The stock of Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) last traded at $2.13, down -8.19% from the previous session.
As we calculate the median target price by taking the range between a high of $30.00 and a low of $11.00, we find $20.00. Given the previous closing price of $2.32, this indicates a potential upside of 762.07 percent. PRTK stock price is now 1.67% away from the 50-day moving average and -10.64% away from the 200-day moving average. The market capitalization of the company currently stands at $119.28M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Brokers who have rated the stock have averaged $20.33 as their price target over the next twelve months.
With the price target maintained at $11, WBB Securities recently Upgraded its rating from Buy to Strong Buy for Paratek Pharmaceuticals Inc. (NASDAQ: PRTK). On April 23, 2021, WBB Securities Upgraded its previous ‘Speculative Buy’ rating to ‘Buy’ on the stock increasing its target price from $6 to quote $10, while ‘Jefferies’ rates the stock as ‘Buy’.
In other news, Woodrow Adam, President & Chief Commercial sold 6,750 shares of the company’s stock on Dec 21. The stock was sold for $13,432 at an average price of $1.99. Upon completion of the transaction, the President & Chief Commercial now directly owns 651,284 shares in the company, valued at $1.39 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 21, CEO Loh Evan sold 23,489 shares of the business’s stock. A total of $46,743 was realized by selling the stock at an average price of $1.99. This leaves the insider owning 1,208,198 shares of the company worth $2.57 million. Insiders disposed of 370,957 shares of company stock worth roughly $0.79 million over the past 1 year. A total of 7.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PRTK stock. A new stake in Paratek Pharmaceuticals Inc. shares was purchased by SIMPLEX TRADING, LLC during the first quarter worth $550,000. Y-INTERCEPT (HONG KONG) LTD invested $40,000 in shares of PRTK during the first quarter. In the first quarter, JANE STREET GROUP, LLC acquired a new stake in Paratek Pharmaceuticals Inc. valued at approximately $30,000. WALLEYE CAPITAL LLC acquired a new stake in PRTK for approximately $26,000. AMALGAMATED FINANCIAL CORP. purchased a new stake in PRTK valued at around $17,000 in the second quarter. In total, there are 114 active investors with 46.40% ownership of the company’s stock.
With an opening price of $2.3700 on Wednesday morning, Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) set off the trading day. During the past 12 months, Paratek Pharmaceuticals Inc. has had a low of $1.60 and a high of $4.44. The fifty day moving average price for PRTK is $2.0950 and a two-hundred day moving average price translates $2.3837 for the stock.
The latest earnings results from Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.33, beating analysts’ expectations of -$0.34 by 0.01. This compares to -$0.37 EPS in the same period last year. The net profit margin was -76.10% and return on equity was 60.80% for PRTK. The company reported revenue of $30.21 million for the quarter, compared to $24.45 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 23.59 percent. For the current quarter, analysts expect PRTK to generate $34.19M in revenue.
Moreover, the firm recently paid out its quarterly dividend on 10/29/2014. Investors who held shares on 10/24/2014 were paid a $0.6674 dividend.
Paratek Pharmaceuticals Inc.(PRTK) Company Profile
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
